Skip to contentA
Atara Biotherapeutics, Inc.
A
ATRAAtara Biotherapeutics, Inc. Released May 4, 2017, after the close
10-Q filed May 4, 2017, 34 days after period end · 0001564590-17-008828
Q1 2017 · 10-Q
Revenue—
Net Income-$25.65M-$25.65MN/M vs Q1 2016N/M vs Q4 2016 EPS, diluted
No earnings release is on file for this quarter. Its figures came with the 10-Q.
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Atara Biotherapeutics, Inc. · CIK 1604464 · Engraved from SEC EDGAR
—
Operating Income-$26,161,000N/M Operating Cash Flow-$22,034,000N/M Free Cash Flowderived-$23,240,000N/M ended Mar 31, 2017 · filed May 4, 2017 · 34 d after period end
14.2% from the close of May 2, 2017 to the close of May 8, 2017, the first after the release.
after the close$16.60$14.25 Apr 6May 4Jun 5